

## **Supplementary Materials**

**Table S1.** Variable Definitions

**Figure S1.** Cohort Diagram

**Table S2.** NSAID and antiplatelet medications

**Table S3.** Predicted probability of anticoagulant initiation in patients with primary admission diagnosis of atrial fibrillation

**Table S4.** Adjusted odds of anticoagulant initiation among all patients by race and geriatric conditions


**Table S1.** Variable Definitions

| Variable                               | Definition/Codes  |
|--|---|
| Atrial fibrillation                    | Atrial fibrillation Chronic Conditions Warehouse Algorithm (CCW). <sup>16</sup><br><br>ICD-10: I48.0, I48.1, I48.11, I48.19, I48.2, I48.20, I48.21, I48.91 (only first or second diagnosis on the claim)<br>ICD-9: 427.31 (only first or second diagnosis on the claim)   |
| Frailty                                | Claims-Based Frailty Index <sup>25</sup>  |
| CHA <sub>2</sub> DS <sub>2</sub> -VASc | Heart Failure (CCW)- 1 point<br>Hypertension (CCW) - 1 point<br>Age 65-74- 1 point<br>Age 75+- 2 points<br>Diabetes (CCW)- 1 point<br>Stroke / transient ischemic attack (CCW)- 2 points<br>Ischemic heart disease or peripheral vascular disease (CCW)- 1 point<br>Female sex- 1 point   |
| HAS-BLED                               | Hypertension (CCW)- 1 point<br>Chronic kidney disease (CCW)- 1 point<br>Liver Disease, Cirrhosis and Other Liver Conditions (CCW) - 1 point<br>Stroke / transient ischemic attack (CCW) - 1 point<br>Clinically significant bleeding (History of a hospitalization with a primary diagnosis among the ICD-9 or ICD-10 codes listed below under “Bleeding” within 1 year prior to index hospitalization) <sup>21,22</sup> - 1 point<br>Age > 65- 1 point<br>Filled script for NSAID or anti-platelet drug in <b>Table S2</b> within 1 year- 1 point<br>Alcohol use disorders (CCW) - 1 point |
| Primary admission category             | Circulatory<br>Other non-cardiac (Hematologic, Mental Health, Nervous System, Circulatory, Respiratory, Digestive, Genitourinary, Skin, Musculoskeletal, Congenital, Injury/Poisoning, Signs/Symptoms, Residual)  |
| Post-cardiac surgery                   | Claim for primary admission included:<br>Centers for Disease Control and Prevention National Healthcare Safety Network Code for Cardiac Surgery (CARD) OR<br>Clinical Classifications Software Refined category for Coronary Artery Bypass Graft and Heart Transplant   |
| Hospitalization for bleeding           | Admission for which the primary diagnosis was any of the diagnosis codes listed below under “Bleeding” <sup>21,22</sup>   |
| Dementia                               | Alzheimer's Disease and Related Disorders or Senile Dementia CCW <sup>27</sup><br><br>ICD-10: F01.50, F01.51, F02.80, F02.81, F03.90, F03.91, F04, F05, F06.1, F06.8, G13.8, G30.0, G30.1, G30.8, G30.9, G31.01, G31.09, G31.1, G31.2, G94, R41.81, R54 (any diagnosis on the claim)<br>ICD-9: 331.0, 331.11, 331.19, 331.2, 331.7, 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 290.43, 294.0, 294.10, 294.11, 294.20, 294.21, 294.8, 797 (any diagnosis on the claim)  |
| Falls                                  | 1 year prior to index date (date of admission) among inpatient, skilled nursing facility, home health agency, HOP, or carrier claims<br><br>ICD-10: W00-W19<br>ICD-9: E880, E881, E882, E883, E884, E885, E886, E888  |
| Delirium                               | Any ICD-9 or 10 code for delirium billed during index hospitalization <sup>28</sup><br><br>ICD-10: A812, E512, F05, F10121, F10221, F10231, F10921, F11121, F11221, F11921, F12121, F12221, F12921, F13121, F13221, F13231, F13921, F13931, F14121, F14221, F14921, F15121, F15221, F15921, F16121, F16221, F16921,   |

|                                  |  |
|----------------------------------|--|
|                                  | F18121, F18221, F18921, F19121, F19221, F19231, F19921, F19931, G0430, G0431, G0432, G0439, G92, G9340, G9341, G9349, I673, I674, I6783, J1081, J1181, P9160, P9161, P9162, P9163<br>ICD-9: 290.11, 290.12, 290.13, 290.2, 290.3, 290.41, 290.43, 290.9, 291, 292, 292.11, 292.12, 292.2, 292.81, 292.82, 293, 293.1, 293.81, 293.82, 293.83, 293.84, 293.89, 293.9, 348.3, 348.31, 348.39, 349.82, 780.02, 780.09, 780.97   |
| Comorbidity                      | Elixhauser Comorbidity Index <sup>29</sup>   |
| Cardiac monitoring <sup>17</sup> | Any claim for one of the following Current Procedural Terminology codes:<br><br>93224, 93225, 93226, 93227, 93228, 93229, 93241, 93242, 93243, 93244, 93245, 93246, 93247, 93248, 93268, 93270, 93271, 93272   |
| Bleeding <sup>21,22</sup>        | ICD-10:<br><u>Gastrointestinal:</u> K55.2x, K31.811, K57.01, K57.11, K57.13, K57.21, K57.31, K57.33, K57.41, K57.51, K57.53, K57.81, K57.91, K57.93, K26.2, K26.4, K26.6, I85.x, K25.0, K25.2, K25.4, K25.6, K29.01, K29.21, K29.31, K29.41, K29.51, K29.61, K29.81, K29.91, K92.2, K28.0, K28.2, K28.4, K28.6, K92.0, R04.xx, K62.5, K64.x, K92.1, K27.0, K27.2, K27.4, K27.6, K22.6<br><u>Intracranial:</u> I61.x, I60.xx, I62.xx, S06.6, S06.5<br><u>Gynecologic:</u> N93.9, N92.0, N92.1, N92.4, N93.8, N95.0<br><u>Other:</u> D62, S06.4, M25.0xx, R31.xx, I31.2, K66.1, R04.xx, R58.0, J94.2, J94.2, H92.2, N02, H35.6, R23.3, H43.1, H45.0, R04.x<br><br>ICD-9:<br><u>Gastrointestinal:</u> 569.85, 537.83, 562.02, 562.03, 562.12, 562.13, 532, 532.2x, 532.4x, 532.6x, 456.2x, 456, 531.xx, 535.01, 535.11, 535.31, 535.41, 535.51, 535.61, 578.x, 534.4x, 578.0, 786.3x, 569.3, 455.x, 578.1, 533.2x, 533.4x, 530.7<br><u>Intracranial:</u> 431, 430, 432.x, 852<br><u>Gynecologic:</u> 626.9, 626.2, 626.6, 627, 626.8, 627.1<br><u>Other:</u> 285.1, 719.1x, 599.7x, 423, 423, 786.3x, 860.2, 860.3, 362.81, 782.7, 379.23, 784.7, 784.8 |

Abbreviations: NSAID = non-steroidal anti-inflammatory drug

**Figure S1. Cohort Diagram**



**Table S2.** NSAID and antiplatelet medications<sup>21</sup>

| <b>NSAIDs</b> | <b>Antiplatelet medications</b> |
|---------------|---------------------------------|
| aspirin       | abciximab                       |
| ibuprofen     | aspirin                         |
| ketoprofen    | clopidogrel                     |
| naproxen      | prasugrel                       |
| ketorolac     | ticagrelor                      |
| indomethacin  | ticlopidine                     |
| sulindac      | cangrelor                       |
| ketorolac     | cilostazole                     |
| piroxicam     | dipyridamole                    |
| nabumetone    | eptifibatide                    |
| etodolac      | tirofiban                       |
| meloxicam     |                                 |
| diclofenac    |                                 |
| celecoxib     |                                 |
| rofecoxib     |                                 |
| valdecoxib    |                                 |

Abbreviations: NSAID = non-steroidal anti-inflammatory drug

**Table S3.** Predicted probability of anticoagulant initiation in patients with primary admission diagnosis of atrial fibrillation

| <b>Predicted probability of anticoagulant initiation (95% CI)</b> |                        |
|---|------------------------|
| <b>Thromboembolic Risk <sup>a</sup></b>                           |                        |
| Low   | 39.9% (36.8% to 42.9%) |
| Moderate  | 45.1% (43.1% to 47.0%) |
| High  | 46.7% (45.5% to 47.9%) |
| <b>Bleeding Risk <sup>b</sup></b>                                 |                        |
| Low   | 47.5% (45.7% to 49.2%) |
| Moderate  | 47.9% (46.5% to 49.2%) |
| High  | 44.1% (42.8% to 45.5%) |
| <b>Frailty Category</b>   |                        |
| Not frail   | 46.8% (44.4% to 49.2%) |
| Prefrail  | 48.6% (47.4% to 49.8%) |
| Mildly frail  | 44.0% (42.4% to 45.7%) |
| Moderately-severely frail   | 36.2% (33.5% to 39.0%) |

<sup>a</sup> For thromboembolic risk, CHA<sub>2</sub>DS<sub>2</sub>-VASc score <2 was considered low, 2-3 moderate, and ≥4 high. CHA<sub>2</sub>DS<sub>2</sub>-VASc score includes congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex.

<sup>b</sup> For bleeding risk, HAS-BLED score <2 was considered low, 2 moderate and ≥3 high. HAS-BLED score includes hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly (age ≥65 years), and drugs or alcohol.

**Table S4.** Adjusted odds of anticoagulant initiation among all patients by race and geriatric conditions

|                             | Initiated anticoagulation within 7 days |                     | Initiated anticoagulation within 30 days |                     |
|-----------------------------|---|---------------------|--|---------------------|
|                             | N (% <sup>a</sup> )                     | Odds ratio (95% CI) | N (% <sup>a</sup> )                      | Odds ratio (95% CI) |
| <b>Race/ethnicity</b>       |   |                     |  |                     |
| White                       | 8,004/31,955 (25.0%)                    | Reference           | 10,176/31,955 (31.8%)                    | Reference           |
| Asian/Pacific Islander      | 178/809 (22.0%)                         | 1.04 (0.87,1.25)    | 211/809 (26.1%)                          | 0.94 (0.80,1.12)    |
| Black                       | 608/2,974 (20.4%)                       | 0.94 (0.85,1.04)    | 741/2,974 (24.9%)                        | 0.88 (0.80,0.96)    |
| Hispanic                    | 453/2011 (22.5%)                        | 1.00 (0.90,1.13)    | 537/2011 (26.7%)                         | 0.91 (0.81,1.01)    |
| Other                       | 169/630 (26.8%)                         | 1.14 (0.95,1.38)    | 210/630 (33.3%)                          | 1.12 (0.93,1.34)    |
| <b>Geriatric conditions</b> |   |                     |  |                     |
| Dementia                    | 845/5,779 (14.6%)                       | 0.66 (0.61,0.72)    | 1,039/5,779 (18.0%)                      | 0.61 (0.57,0.66)    |
| Falls                       | 131/772 (17.0%)                         | 0.84 (0.69,1.02)    | 160/772 (20.7%)                          | 0.78 (0.65,0.95)    |
| Delirium                    | 297/2,002 (14.8%)                       | 0.95 (0.83,1.09)    | 365/2002 (18.2%)                         | 0.94 (0.83,1.06)    |

<sup>a</sup>. Percent of all study subjects.